Association of Kaposi’s Sarcoma–Associated Herpesvirus Viral Load With 12-Week Mortality
| Group . | KSHV Viral Load . | Died, No. (%) . | Survived, No. (%) . | OR (95% CI) . | P Valuea . |
|---|---|---|---|---|---|
| Group 1: Entire patient cohort (n = 675) | >100 copies/106 cells | 9 (1.3) | 24 (3.6) | 1.3 (.6–3.0) | .455b |
| ≤100 copies/106 cells or nondetectable | 137 (20.3) | 493 (73.0) | |||
| Group 2: Patients with microbiologically proven TB (n = 500) | >100 copies/106 cells | 3 (0.4) | 20 (3.0) | 0.5 (.2–1.7) | .281b |
| ≤100 copies/106 cells or nondetectable | 106 (15.7) | 363 (53.8) | |||
| Group 3: Patients without proven TB (n = 175) | >100 copies/106 cells | 6 (0.9) | 4 (0.6) | 6.3 (1.7–23.7) | .008c |
| ≤100 copies/106 cells or nondetectable | 31 (4.6) | 130 (19.3) | |||
| Group 4: Patients without microbiologically confirmed infections (n = 159) | >100 copies/106 cells | 5 (0.7) | 3 (0.4) | 7.1 (1.6–31.7) | .011c |
| ≤100 copies/106 cells or nondetectable | 28 (4.1) | 120 (17.8) |
| Group . | KSHV Viral Load . | Died, No. (%) . | Survived, No. (%) . | OR (95% CI) . | P Valuea . |
|---|---|---|---|---|---|
| Group 1: Entire patient cohort (n = 675) | >100 copies/106 cells | 9 (1.3) | 24 (3.6) | 1.3 (.6–3.0) | .455b |
| ≤100 copies/106 cells or nondetectable | 137 (20.3) | 493 (73.0) | |||
| Group 2: Patients with microbiologically proven TB (n = 500) | >100 copies/106 cells | 3 (0.4) | 20 (3.0) | 0.5 (.2–1.7) | .281b |
| ≤100 copies/106 cells or nondetectable | 106 (15.7) | 363 (53.8) | |||
| Group 3: Patients without proven TB (n = 175) | >100 copies/106 cells | 6 (0.9) | 4 (0.6) | 6.3 (1.7–23.7) | .008c |
| ≤100 copies/106 cells or nondetectable | 31 (4.6) | 130 (19.3) | |||
| Group 4: Patients without microbiologically confirmed infections (n = 159) | >100 copies/106 cells | 5 (0.7) | 3 (0.4) | 7.1 (1.6–31.7) | .011c |
| ≤100 copies/106 cells or nondetectable | 28 (4.1) | 120 (17.8) |
Frequency of mortality among patients with elevated KSHV viral load (>100 copies/106 cells) vs those with undetectable KSHV viral load or viral load ≤100 copies/106 cells. Twelve patients of the total cohort were lost to follow-up.
Abbreviations: CI, confidence interval; KSHV, Kaposi’s sarcoma–associated herpesvirus; OR, odds ratio; TB, tuberculosis.
aP value refers to the frequency of elevated KSHV viral load (categorical variable) in patients with confirmed vital status.
bχ2 test for association if expected cell frequencies were >5.
cFisher exact test.
Association of Kaposi’s Sarcoma–Associated Herpesvirus Viral Load With 12-Week Mortality
| Group . | KSHV Viral Load . | Died, No. (%) . | Survived, No. (%) . | OR (95% CI) . | P Valuea . |
|---|---|---|---|---|---|
| Group 1: Entire patient cohort (n = 675) | >100 copies/106 cells | 9 (1.3) | 24 (3.6) | 1.3 (.6–3.0) | .455b |
| ≤100 copies/106 cells or nondetectable | 137 (20.3) | 493 (73.0) | |||
| Group 2: Patients with microbiologically proven TB (n = 500) | >100 copies/106 cells | 3 (0.4) | 20 (3.0) | 0.5 (.2–1.7) | .281b |
| ≤100 copies/106 cells or nondetectable | 106 (15.7) | 363 (53.8) | |||
| Group 3: Patients without proven TB (n = 175) | >100 copies/106 cells | 6 (0.9) | 4 (0.6) | 6.3 (1.7–23.7) | .008c |
| ≤100 copies/106 cells or nondetectable | 31 (4.6) | 130 (19.3) | |||
| Group 4: Patients without microbiologically confirmed infections (n = 159) | >100 copies/106 cells | 5 (0.7) | 3 (0.4) | 7.1 (1.6–31.7) | .011c |
| ≤100 copies/106 cells or nondetectable | 28 (4.1) | 120 (17.8) |
| Group . | KSHV Viral Load . | Died, No. (%) . | Survived, No. (%) . | OR (95% CI) . | P Valuea . |
|---|---|---|---|---|---|
| Group 1: Entire patient cohort (n = 675) | >100 copies/106 cells | 9 (1.3) | 24 (3.6) | 1.3 (.6–3.0) | .455b |
| ≤100 copies/106 cells or nondetectable | 137 (20.3) | 493 (73.0) | |||
| Group 2: Patients with microbiologically proven TB (n = 500) | >100 copies/106 cells | 3 (0.4) | 20 (3.0) | 0.5 (.2–1.7) | .281b |
| ≤100 copies/106 cells or nondetectable | 106 (15.7) | 363 (53.8) | |||
| Group 3: Patients without proven TB (n = 175) | >100 copies/106 cells | 6 (0.9) | 4 (0.6) | 6.3 (1.7–23.7) | .008c |
| ≤100 copies/106 cells or nondetectable | 31 (4.6) | 130 (19.3) | |||
| Group 4: Patients without microbiologically confirmed infections (n = 159) | >100 copies/106 cells | 5 (0.7) | 3 (0.4) | 7.1 (1.6–31.7) | .011c |
| ≤100 copies/106 cells or nondetectable | 28 (4.1) | 120 (17.8) |
Frequency of mortality among patients with elevated KSHV viral load (>100 copies/106 cells) vs those with undetectable KSHV viral load or viral load ≤100 copies/106 cells. Twelve patients of the total cohort were lost to follow-up.
Abbreviations: CI, confidence interval; KSHV, Kaposi’s sarcoma–associated herpesvirus; OR, odds ratio; TB, tuberculosis.
aP value refers to the frequency of elevated KSHV viral load (categorical variable) in patients with confirmed vital status.
bχ2 test for association if expected cell frequencies were >5.
cFisher exact test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
